CCL2 and renal cell carcinoma: To examine the effect of inhibiting CCL2 activity in the clinical relevant RCC model, we administered CCL2 neutralizing antibodies to primary RCC xenografts, which similarly resulted in significant suppression of tumor growth, angiogenesis, and macrophage infiltration.